Carboplatin-paclitaxel With Retifanlimab or Placebo in Participants With Locally Advanced or Metastatic Squamous Cell Anal Carcinoma (POD1UM-303/InterAACT 2).
Public ClinicalTrials.gov record NCT04472429. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3 Global, Multicenter, Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study is a Phase 3 global, multicenter, placebo-controlled double-blind randomized study that will enroll participants with inoperable locally recurrent or metastatic SCAC not previously treated with systemic chemotherapy.
Study identification
- NCT ID
- NCT04472429
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 308 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 9, 2020 (Actual)
- Primary completion
- Apr 15, 2024 (Actual)
- Completion
- Sep 26, 2025 (Actual)
- Last update posted
- Sep 25, 2026
2020 – 2025
United States locations
- U.S. sites
- 14
- U.S. states
- 8
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| The University of Arizona Cancer Center | Tucson | Arizona | 85724 | — |
| City of Hope National Medical Center | Duarte | California | 91010 | — |
| UC Davis Comprehensive Cancer Center | Sacramento | California | 95817 | — |
| Sansum Clinic | Santa Barbara | California | 93105 | — |
| Rocky Mountain Cancer Center | Denver | Colorado | 80218 | — |
| Ochsner Clinic | New Orleans | Louisiana | 70121 | — |
| Maryland Oncology Hematology, P.A. | Columbia | Maryland | 21044 | — |
| Mayo Clinic | Rochester | Minnesota | 55905 | — |
| Texas Oncology | Austin | Texas | 78745 | — |
| Baylor Scott and White Research Institute | Dallas | Texas | 75246 | — |
| Renovatio Clinical Consultants Llc | The Woodlands | Texas | 77380 | — |
| Texas Oncology-Wichita Falls Texoma Cancer Center | Wichita Falls | Texas | 76310 | — |
| Virginia Cancer Specialists, Pc | Arlington | Virginia | 22205 | — |
| Blue Ridge Cancer Care | Roanoke | Virginia | 24014 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 69 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04472429, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 25, 2026 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04472429 live on ClinicalTrials.gov.